STAT6 Degrader

AK-1690 is a selective PROTAC degrader targeting STAT6 (DC₅₀=1 nM) with a K_i of 6 nM against human STAT6. AK-1690 degrades STAT6 via the interaction of STAT6 with cereblon and a ubiquitin-like process. AK-1690 effectively depletes STAT6 protein in mouse liver and lung tissues, and is applicable to research related to leukemia, Hodgkin's lymphoma, follicular lymphoma, etc..

STAT6 degrader-3 is a potent, bifunctional STAT6 degrader that recruits STAT6 to an E3 ubiquitin ligase, promoting STAT6 ubiquitination and subsequently inducing its degradation. STAT6 degrader-3 can be used in research concerning STAT6-related inflammation and immune signaling.

SD-436 is a highly selective and efficacious STAT3 PROTAC degrader (DC₅₀: 0.5 μM), with IC₅₀ of 19 nM (STAT3), 270 nM (STAT1), 360 nM (STAT4), >10 μM (STAT5) and >10 μM (STAT6). SD-436 promotes ubiquitination and degradation of STAT3, and induces tumor regression. SD-436 can be used for tumor research, such as leukemia and lymphoma.

PROTAC STAT6 degrader-1 (Compound I-2) is a potent STAT6 PROTAC degrader with a DC₅₀ <1 nM. PROTAC STAT6 degrader-1 inhibits STAT6 activity with an IC₅₀ of <0.1 pM. PROTAC STAT6 degrader-1 can be used for inflammatory and cancers research, such as non-small cell lung cancer (NSCLC).

STAT6 degrader-4 (Compound I-197) is a STAT6 degrading agent with a DC₅₀ value ranging from 1 to 10 μM. STAT6 degrader-4 can be used in cancer research.

PROTAC STAT6 degrader-7 is a STAT6 PROTAC degrader with an IC₅₀ of <0.1 μM. PROTAC STAT6 degrader-7 promotes ubiquitination and degradation of STAT6. PROTAC STAT6 degrader-7 can be used in cancer research.

PROTAC STAT6 degrader-8 is a STAT6 PROTAC degrader with a DC₅₀ value >0.1 μM and a DC_max value > 0.01 μM. PROTAC STAT6 degrader-8 has the potential for application in inflammation-related diseases.

PROTAC STAT6 degrader-5 is a PROTAC degrader that selectively targets STAT6. PROTAC STAT6 degrader-5 induces the degradation of STAT6 protein. PROTAC STAT6 degrader-5 can be used in inflammation and cancer research.

PROTAC STAT6 degrader-9 is a STAT6 PROTAC degrader with a DC₅₀ value >1 μM and a DC_max value > 0.1 μM. PROTAC STAT6 degrader-9 has the potential for application in inflammation-related diseases.

PROTAC STAT6 degrader-11 is a STAT6 PROTAC degrader that recruits E3 ubiquitin ligase to induce degradation via the proteasomal pathway. STAT6 degrader-1 can be used in the research of cancer and inflammatory diseases.

PROTAC STAT6 degrader-2 is a STAT6-selective PROTAC degrader. PROTAC STAT6 degrader-2 is used for the research of STAT6-mediated diseases.

PROTAC STAT6 degrader-10 is a bifunctional STAT6 degrader with a DC₅₀ value of >1 μM. PROTAC STAT6 degrader-10 recruits STAT6 protein to E3 ubiquitin ligase for ubiquitination and subsequent degradation. PROTAC STAT6 degrader-10 can be used for the research of inflammatory disorders, allergies, asthma, eczema.

PROTAC STAT6 degrader-4 (Compound 3u247) is a STAT6 PROTAC degrader with a DC₅₀ of 0.04 nM. PROTAC STAT6 degrader-4 promotes the ubiquitination and degradation of STAT6, and is applicable to the research of immune diseases.